04:44 PM EST, 03/04/2026 (MT Newswires) -- Aquestive Therapeutics ( AQST ) reported a Q4 loss late Wednesday of $0.26 per diluted share, widening from the loss of $0.19 a year earlier.

Analysts surveyed by FactSet expected a loss of $0.13.

Revenue in the three months ended Dec. 31 rose to $13 million from $11.9 million a year earlier.

Analysts polled by FactSet expected $13.3 million.

Aquestive Therapeutics ( AQST ) expects 2026 revenue of $46 million to $50 million. Analysts expect $47.5 million.

The company's shares fell 3.9% in after-hours trading.